Clinical Trials Directory

Trials / Terminated

TerminatedNCT02679404

Sorin Universal REgistry on Aortic Valve Replacement

Status
Terminated
Phase
Study type
Observational
Enrollment
2,758 (actual)
Sponsor
Corcym S.r.l · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Multi-center, International, Prospective, Non comparative, Non randomized, Open label. 5,000 patients to be enrolled approximately worldwide. The objective of this registry is to collect safety and clinical performance post market data related to the procedure and follow-up of the Sorin Group aortic valve devices in accordance with the Instructions for Use (IFU). This observational global registry is intended to collect data without requiring any deviation from the standard of care and IFU in each participating center. The participating centers shall include those patients that have provided their informed consent to participate in this registry in accordance with the local applicable regulations.

Detailed description

SURE-AVR objective is to collect post market safety and performance data collected along the procedure and the relevant follow-up with Sorin Group aortic valve devices in accordance with the IFU to further evidence the safety and efficacy in a post-approval environment. All current and future Sorin Group aortic valve devices that have obtained CE-mark or other local regulatory and/or commercial approvals may be included in the registry. During the duration of the registry,other aortic valve replacement products or current devices might receive modifications and might become commercial available. This registry allows extensions for the inclusion of new products. This observational global registry is intended to collect data without requiring any deviation from the standard of care and IFU in each participating center. The participating centers shall include those patients that have provided their informed consent to participate in this registry following the local applicable regulations. The data collection shall be performed as per the local standard of care and without exposing the patient to any additional risk to the treatment (s)he would normally receive. The registry is an open-ended project: * Inclusions phase: open-ended * Follow-up phase: annually throughout 5 years (7 and 10 years are optional). The study shall be completed after the 10-year follow-up of the last patient.

Conditions

Timeline

Start date
2015-05-01
Primary completion
2021-03-01
Completion
2021-03-01
First posted
2016-02-10
Last updated
2024-03-06

Locations

52 sites across 17 countries: United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Israel, Italy, Netherlands, Singapore, Slovakia, Spain, Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT02679404. Inclusion in this directory is not an endorsement.